Human endogenous retroviruses (HERVs) comprise up to 8% of the human genome. In previous studies, we demonstrated that type 1 HERV-K envelope (env) transcripts are expressed in most human breast cancers, but not in normal breast tissues. In the current study, we report that type 2 HERV-K env transcripts are also present in human breast cancers. By real-time RT-PCR, the expression of HERV-K env transcripts was 5-10-fold higher in breast cancer cell lines treated with estradiol and progesterone than in cells without treatment, and expression was significantly higher in most breast cancer tissues than in normal breast tissues. Furthermore, both types of HERV-K env transcripts were capable of being spliced into subgenomic env transcripts and various splice donor and acceptor sites were detected in breast cancers. The selective expression and distribution of multiple HERV-K endogenous retroviral element splice variants in breast cancer, but not in normal controls, suggests that they are novel breast tumor markers.
Human endogenous retroviruses (HERVs) comprise up to 8% of the human genome, as analysed by the Human Genome Sequencing Project (Lander et al., 2001) . As a rule, retroviruses start to lose infectivity as a result of the accumulation of mutations, a process accentuated by selection against a replicating pathogen. These HERVs are mostly noninfectious, replication-defective, retroviral remnants transmitted as stable Mendelian genes. However, in humans, reports of detection of HERV mRNA, HERV proteins, and even HERV particles in human diseases, especially cancer, have increased in recent years. The pathogenic potential of nondefective endogenous retroviruses has so far only been demonstrated in mice, in which they may induce tumors and immunological disorders (Asch et al., 1993; Natoli et al., 1996) . It has been suggested that there are 170 copies of HERV-K genomic DNA within the human genome (Tristem, 2000) . Several other reports suggest the existence of at least 10 different sequence families in the human genome with varying degrees of homology to HERV-K10 and mouse mammary tumor virus (MMTV) pol genes, as well as to each other (Franklin et al., 1988; Medstrand and Blomberg, 1993; Barbulescu et al., 1999) .
Of the many HERV families, only K appears to have the full complement of open reading frames (ORFs) typical of replication-competent mammalian retroviruses (LTR-gag-pro/pol-env-LTR) (Ono et al., 1986; Mayer et al., 1999) . HERV-K retrovirus-like particles that encode for viral particles in the teratocarcinoma cell line GH (Lower et al., 1993; Lower et al., 1995) and the breast cancer cell line T47D (Ono et al., 1987) have been described. In teratocarcinoma cell lines, HERV-K gag genes are expressed, leading to the production of viral core proteins and virus particles (Lower et al., 1995) .
Previously, we reported that type 1 HERV-K transcripts with coding potential for the envelope region are expressed frequently in human breast cancer. In this study, we investigated expression of type 2 HERV-K env mRNAs and the splicing pattern of both types of HERV-K in human breast cancer tissues. Messenger RNA was isolated from 31 breast cancers; cDNAs were then synthesized. A sense primer specific to the 292 bp region of HERV-K type 2 (5 0 -GTATGCTGCTTG-CAGCCTTGATGAT-3 0 , nucleotide (nt) 6674-6698; Accession number: AF074086, Figure 1a ) (Mayer et al., 1999) , and the same HERV-K antisense primer described previously (Wang-Johanning et al., 2001 ) were used to detect type 2 HERV-K env transcripts by RT-PCR in human breast cancer tissues. Some breast cancer tissues expressed only type 1 (1104 bp; Figure 1b , upper panel) HERV-K env transcripts, some expressed only type 2 (1194 bp; Figure 1b , middle panel), and some expressed both types of HERV-K env region transcripts with the same or varying intensities. b-Actin was used as an internal control for each amplified cDNA sample (Figure 1b, lower panel) . Of the human breast cancer samples analysed by RT-PCR, 71% of breast cancer samples were positive for HERV-K type 1 mRNA expression and 52% were positive for type 2 expression (n ¼ 31 HERV-K positive breast cancer samples). The RT-PCR products obtained from an invasive ductal carcinoma (BC3; Figure 1b) were completely sequenced and the results are shown in Table 1 . Three clones representing type 1 HERV-K were 99-100% homologous to HERV-K 102 (the prototypical HERV-K type 1 sequence) with 0-3 bp difference (in a total 1104 bp amplified). Meanwhile, of five clones containing a 292 bp insert representing type 2 HERV-K, three of five were 98% homologous to HERV-K 109 (Accession number: AF164615) (Barbulescu et al., 1999) with at least 13 bp difference in a total of 1194 bp, and two of five were 97-98% homologous to HERV-K (I) (Accession number: AB047209.1) (Sugimoto et al., 2001) .
The predominance of full-length type 1 HERV-K provirus transcript expression over type 2 expression was verified by Northern blot analysis in our earlier study (Wang-Johanning et al., 2001 ). In the current study, full-length HERV-K provirus transcription was detected in human breast cancer tissues Figure 1a ) and P3 antisense (CAATCTTGTAGAATTCTTTTGCC, env region, nt 7690-7668, according to HERV-K102) primers described previously (Lower et al., 1995) . This primer pair amplifies only cDNA derived from full-length transcripts because the sequences to which the P1 primer binds in the gag/pol intron are spliced out into subgenomic env mRNAs. PCR using primers P1 and P3 to amplify human breast cancer mRNAs revealed a band at 1616 bp (type 1; see Figure 1c ; lower band) in most HERV-K-positive breast cancers and a band at 1908 (type 2; upper band) in a minority HERV-K-positive cancers ( Figure 1c) . Two clones representing full-length type 1 HERV-K transcripts were obtained from an invasive ductal carcinoma (BC3 from Figure 1b ) and sequenced. These clones showed 95-98% homology to HERV-K (II) and HERV-K 102 sequences (Table 1) .
The expression of HERV-K was increased if T47D cells were treated with b-estradiol (10 nm) on day 1 followed by progesterone (100 nm) on day 2 as described by our group and others (Ono et al., 1987) (Figure 2a) . Therefore, the change in expression of HERV-K in breast cancer cells in response to hormones was quantified by real-time RT-PCR. The HERV-K primers and probes used were: forward (TaqFWD; 5 0 -ATTGG-CAACACCGTATTCTGCT-3 0 ; nt 7413-7434 according to HERV-K102 sequence or 7706-7727 according to HML-2.HOM sequence), reverse (TaqREV; 5 0 -CAGT-CAAAATATGGACGGATGGT-3 0 ; nt 7517-7495 for K102 or 7810-7789 for HML-2.HOM sequence) and probe (TaqProbe; 5 0 -FAM-ACACAGGGATCCA-CACGCCCTCTCTT-TAMRA-3 0 ; nt 7469-7444 for HERV-K102 or 7762-7737 for HML-2.HOM sequence). The HERV-K primers and probe for TaqMan real-time RT-PCR are able to amplify a 155 bp length PCR product from both types of HERV-K env regions from HERV-K10 (HUMERVKA), HERV-K102 (AF164610), HERV-K103 (AF164611), HERV-K104 (AF164612), HERV-K107 (AF164613), HERV-K108 (AF164614), HERV-K109 (AF164615), HERV-K113 (AY037928.1), HERV-K115 (AY037929.1), and HML-2.HOM (AF074086.2). Using glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Perkin-Elmer, Foster City, CA, USA) as an endogenous control, quantitation of the amount of target (copy number/pg GAPDH RNA) in unknown samples is accomplished using the standard curve method, with each unknown HERV-K RNA sample being normalized on the basis of GAPDH content. One-step real-time RT-PCR was performed using an ABI PRISM 7700 sequence detector as follows. Known amounts of HERV-K cRNA molecules (1 Â 10 6 , 1 Â 10 5 , 1Â 10 4 , and 1Â 10 3 copies) were used to generate an absolute standard curve. The copy number of HERV-K mRNA was then determined by linear extrapolation of the C T values using the equation of the line obtained from the absolute HERV standard curve. These values were then divided by the relative amounts of GAPDH in an endogenous control (normal breast RNA; Biochain Institute Inc.). The results (Figure 2b ) clearly indicate that the HERV-K env mRNA copy number per ng RNA increased from 4-10-fold in response to hormone treatment in most of the breast cancer cell lines studied, including BT-20, ZR-75-1, MCF-7, T47D, and SKBr3. However, hormone treatment did not increase copy number in MDA-MB-231 cells, likely because this cell line does not express estrogen and progesterone receptors. The HERV-K env mRNA copy number was lower in normal human mammary epithelial cells (HMEC; Figure 2b ) than in any of the breast cancer cell lines, with or without hormone treatment.
The expression of HERV-K in human breast biopsies was subsequently evaluated by real-time RT-PCR analysis as described previously (Wang-Johanning et al., 2002) . The results of one of these analyses are shown in Figure 2c . The expression of HERV-K env mRNA was elevated in approximately 70-80% of breast cancers compared with normal breast tissues. The ratio of HERV-K mRNA copy number in breast cancers to the average copy number in 10 normal breast control tissues was calculated. The HERV-K env expression increased from six to 20-fold in ductal carcinoma in situ and uninvolved normal epithelial cells; the purity of the populations of cancer and normal cells obtained from the same patient was greater than 90%. Frozen sections fixed in 70% ethanol and stained with hematoxylin and eosin (H&E) stain were used, and cells were microdissected from the sections using an LCM system with an infrared diode laser (PixCell II System, Arcturus Engineering, Mountain View, CA, USA). RNA from the microdissected cells was isolated and treated with DNase, followed by quantitation of the level of expression of HERV-K in the different cell populations by real-time RT-PCR. Real-time RT-PCR quantitation of HERV-K mRNA levels in LCM cells (approximately 300-2000 cells) derived from cancer or uninvolved adjacent epithelium were measured, and the copy number was 5-8-fold greater in tumor epithelial cells than in uninvolved normal epithelial cells in most of the patients studied (data not presented). Approximately 25% of breast cancer tissues showed a very low expression of HERV-K in both tumor cells and adjacent uninvolved ductalobular epithelium obtained by LCM. Factors that contribute to increased HERV-K expression in some breast cancers but not in others are currently unknown.
Expression of both types of HERV-K full-length or env transcripts has been observed by other groups. However, only type 2 HERV-K splicing to a subgenomic env mRNA has been documented in teratocarcinoma cell lines (Lower et al., 1995) , or only type 1 HERV-K splicing to a subgenomic env mRNA has been documented in the T47D cell line (Etkind et al., 1997) . In this study, we employed the same primer pairs described previously to identify type 1 and type 2 splicing patterns (Etkind et al., 1997) . Both types of HERV-K env transcripts were able to undergo splicing into subgenomic env mRNAs (Figure 3 ). Two bands, 790 bp (representing type 2 HERV-K) and 497 bp (representing type 1 HERV-K), were amplified from HERV-K positive breast cells or tissues by RT-PCR using U5 and EnvA primers. The difference in the size of the two bands is 292 bp. Four clones (165U2, 165U4, 165U3, and 165U5), derived from breast cancer patient #165 (BC3; see Figure 1b ) with invasive ductal carcinoma (see Tables 1 and 2) , were amplified via nested RT-PCR using U5 and env A primer pairs (790 bp product). After sequencing, clones #165U2 and 165U4 were found to be 99% homologous to type 2 HERV-K sequences, such as HERVCORF (X82271.1) and HERV-K(HML-2.HOM) (AF074086.2), which contain a 292 bp insert between the pol and env regions. Clones #165U3 and 165U5 were 99 and 98% homologous, respectively, to type 1 HERV-K sequences, such as HERV-K102 (AF164610), which contain the 292 bp deletion.
Also, the splice donor (SD) and splice acceptor (SA) sites, respectively, for type 2 HERV-K were at nt 1076 and 6433, based on HML-2.HOM (AF074086.2) sequence numbering (Table 2) , and for type 1 HERV-K were at nt 876 (following the poly (A) (A) 27 GG(A) 12 tail), and at nt 5997, based on the HERV-K102 sequence (Table 2 ). This is the first report that shows that both types of HERV-K are transcriptionally active in breast cancer.
Importantly, the four clones derived from this breast cancer patient encode ORFs with no stop codons, suggesting that they have the potential for expression at the protein level. Other SD and SA sites derived from breast cancer cell lines and tissues are shown in Table 2 . Clones from other breast cancer cells and tissues (with the exception of MDA-MB-231 and MCF-7 cell lines) did not have defective ORFs, pointing to the potential for env protein expression in breast cancer ( Table 2) . The putative translated proteins from clones representing type 2 HERV-K are highly homologous (>95%) to the HERV-K env protein (AF164614), with a putative nuclear localization signal (NLS; aa 13-20; RRRRHRNR) and a leucine-rich nuclear export signal (NES; aa 53-64; LKKLTQLATKYL) (Boese et al., . The putative translated proteins from clones representing type 1 HERV-K are highly homologous (95%) to the pol/env ORF (AAA88033.1). There were at least two stop codons between the pol and env regions, indicating that the env protein does not undergo fusion with the pol protein in these clones.
The potential for protein expression may explain, in part, why certain viral genes are preferentially activated in breast cancer. In contrast to our observations that the env gene of HERV-K is expressed in breast cancer, Yin et al. (1997) found that the pol gene of HERV-K was no more expressed in malignant than nonmalignant breast tissue. The HERV-K10 gene possesses a pol ORF but disrupted gag and env (Ono et al., 1986) . The variants of HERV-K in breast cancer patients that we describe in our manuscript do not have stop codons in their env ORFs, and thus have the potential to be translated to proteins. If these mRNAs are translated, this may account for increased expression of env but not pol in breast cancer.
Both types of HERV-K env transcripts were detected in T47D cells treated with estradiol and progesterone; however, only type 1 HERV-K splicing in T47D cells was detected and the SD and SA sites were at nt 883 and 6222 according to the HERV-K 102 sequence (AF164610) ( Table 2 ). The type 1 HERV-K splicing pattern was also detected in hormone-treated MCF-7 and MDA-MB-231 breast cancer cell lines, and the SD and SA sites were at nt 2076 and 7599, based on the HERV-K (II) sequences (AB047240). In contrast to clones from most breast cancer cells and tissues, clones derived from teratocarcinoma cells, especially those that were highly homologous to type 1 HERV-K sequences, encoded ORFs with one or more stop codons.
A 311 bp band was detected in T47D cells and in breast cancer tissue using the U5 and env B primer pair. No sequence differences among clones of the 311 bp bands were detected in the breast cancer cell lines or tissues analysed. The PCR product of 311 bp has an SD site at nt 1076 and an SA site at nt 8117, based on the HERV-K102 or nt 8410 based on the HML-2.HOM sequences. The RT-PCR sequences of breast cancer tissues revealed that the stop codon described for the putative env region of HERV-K10 (M1234; Ono et al., 1986) or HERV-K107 (Barbulescu et al., 1999) is absent.
The expression of both types of HERV-K, including full-length HERV-K transcripts, env transcripts, and spliced subgenomic env transcripts, was detected in the majority of human breast cancer tissues analysed. HERV-K expressed in breast cancer has the full complement of ORFs typical of infective retroviruses. The env transcripts of type 1 HERV-K (homology to HERV-K102 and HERV-K (II)) were frequently detected in RT-PCR clones from multiple tissues, but the relative abundance of their transcripts varied among tissues. The env transcripts of type 2 HERV-K revealed more varied transcriptional profiles, with homology to a greater variety of HERV-K sequences. Increased expression of HERV-K env transcripts was associated with hormone treatment, suggesting that hormoneresponsive elements may exist in the regulatory regions of the HERV-K genome.
Our LCM/RT-PCR results raise the question of whether HERV-K expression in breast cancer cells might be specifically associated with tumor development. Such expression might form the basis for using HERV-K as a diagnostic biomarker, and further analysis in cancer would be warranted. Furthermore, both types of HERV-K env transcripts are able to undergo splicing into subgenomic env mRNAs in breast cancer tissues. This suggests that within breast tumor tissue, there are populations of cells that have complex splicing patterns that lead to expression of both types of HERV-K env transcripts. Thus, cell lines or individual cells within a population of tumor cells may express one type of HERV-K env transcript, but cell populations within the tumor are capable of expressing both types of HERV-K env. HERV-K env expression in human breast cancer tissues strongly resembles the pattern observed for exogenous retroviruses: full-length transcripts are accompanied by subgenomic env mRNAs.
In addition, results of our sequence analysis reveal the presence of several novel alternatively spliced HERV env subgenomic transcripts and their smaller spliced products in breast cancer cells or tissues. Multiple SD and SA sites were detected in various breast cancer cell lines (Lower et al., 1995 , Magin et al., 1999 , 2000 Yang et al., 1999; Boese et al., 2000a) . The 14-kDa cORF protein is expressed in teratocarcinoma cell lines (Lower et al., 1995) , and HERV-K cORF was reported to induce tumor formation in nude mice (Boese et al., 2000a) . In the latter study, mice injected with full-length envtransduced Rat-1 cells developed tumors that produced the env splice variant ORF, rather than env itself. This result provides support for the idea that cORF rather than full-length env protein is responsible for cell transformation. Recently, a novel gene, np9, resulting from use of a unique HERV-K type 1-specific splice donor site, was confirmed to be expressed in various tumor tissues and transformed cell lines but not in normal, nontransformed cells, suggesting that the protein may function in tumorigenesis (Armbruester et al., 2002) . It remains to be seen whether the variants that we have identified here will possess tumorigenic properties similar to the np9 variant just reported.
It is important to determine whether the HERV-K splice products are capable of producing proteins, and whether or not these proteins can serve as tumorassociated antigens in breast cancer. Recently, an HERV-K env sequence (HERV-K MEL) encoding an antigen was recognized by cytolytic T lymphocytes obtained from melanoma patients, but not from normal controls (Schiavetti et al., 2002) . Although the 2.5 kb HERV-K MEL sequence contains many mutations that disrupt the ORFs coding for viral proteins, the antigenic peptide is encoded by a very short ORF present in the region of a spliced HERV-K MEL transcript. These results suggest that HERV env proteins or their peptides are a source of tumor-associated antigens. Some of our variant breast cancer clones were found to be capable of protein expression.
In conclusion, our studies have established that increased HERV-K env and spliced env expression is associated with breast cancer. Evaluation of expression of the HERV-K env gene and its splice variants may thus provide a new breast cancer screening tool, and serve as a novel target for detection, diagnosis, and treatment of breast cancer. The potential impact of the unique splice variants that we have described on breast tumorigenesis will require further investigation, but previous studies of other splice variants of the HERV-K env gene suggest that the variants we have described may play a role in the etiology of breast cancer. The results of our studies also indicate that HERV-K proteins are expressed in breast cancer, and therefore are capable of acting as tumor-associated antigens.
